Neurocrine Biosciences, Inc.
NBIX
$131.14
-$1.24-0.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 478.60M | 428.00M | 348.30M | 305.80M | 341.30M |
| Total Depreciation and Amortization | 30.10M | 29.70M | 28.50M | 28.50M | 27.10M |
| Total Amortization of Deferred Charges | -- | -- | -138.40M | -88.70M | 0.00 |
| Total Other Non-Cash Items | 402.80M | 332.80M | 293.00M | 295.60M | 246.20M |
| Change in Net Operating Assets | -128.80M | -153.70M | 35.90M | -11.30M | -19.20M |
| Cash from Operations | 782.70M | 636.80M | 567.30M | 529.90M | 595.40M |
| Capital Expenditure | -34.00M | -43.70M | -38.60M | -37.70M | -38.20M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -230.40M | -236.10M | -19.80M | -19.90M | -88.60M |
| Cash from Investing | -264.40M | -279.80M | -58.40M | -57.60M | -126.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | 0.00 | -308.80M | -308.80M |
| Issuance of Common Stock | 129.40M | 102.10M | 82.90M | 84.30M | 122.10M |
| Repurchase of Common Stock | -167.70M | -467.70M | -467.70M | -450.00M | -300.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -38.30M | -365.60M | -384.80M | -674.50M | -486.70M |
| Foreign Exchange rate Adjustments | 0.00 | -300.00K | 200.00K | 0.00 | 0.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 480.00M | -8.90M | 124.30M | -202.20M | -18.10M |